Congolese journalist helping with Ebola crisis slain
The attack Saturday also left his wife critically injured.
U.S. drugmaker Merck&Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.
[Malawi News Agency] Lilongwe -The Ministry of Health and Population has stressed the need for the country to stay prepared for Ebola disease even though there has been no single confirmed case registered in the country.
The vaccine provided protection from Ebola virus, Sudan virus, Marburg virus and Lassa virus.
Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency
Johnson&Johnson said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck&Co Inc's vaccine.
An eight-month-old boy is examined by a doctor in Dar es Salaam, Tanzania. Credit: Kristin Palitza/IPS By Ifeanyi NsoforABUJA, Nov 7 2019 (IPS) Free movement of people and goods across Africa increases the risk of transmission of infectious diseases. The continent must realise that it is no longer a question of if disease outbreaks will occur, but instead, of when, and how fast. The U.S. Centres for Disease Control says that within 36 hours, a disease outbreak can spread from a remote village to major urban cities of the world. According to preventepidemics.org, a website which ranks countries’ levels of e...
Fifteen confirmed cases were reported in the past week (30 October – 5 November) in the ongoing Ebola virus disease (EVD) outbreak in North Kivu and Ituri provinces
Authors: Villanueva J, Schweitzer B, Odle M, Aden T Abstract The Laboratory Response Network (LRN) was established in 1999 to ensure an effective laboratory response to high-priority public health threats. The LRN for biological threats (LRN-B) provides a laboratory infrastructure to respond to emerging infectious diseases. Since 2012, the LRN-B has been involved in 3 emerging infectious disease outbreak responses. We evaluated the LRN-B role in these responses and identified areas for improvement. LRN-B laboratories tested 1097 specimens during the 2014 Middle East Respiratory Syndrome Coronavirus outbreak, 180 sp...
Condition: Ebola Virus Disease Intervention: Biological: Ad26.ZEBOV, MVA-BN-Filo vaccine Sponsors: London School of Hygiene and Tropical Medicine; Epicentre; Ministère de la Santé de la RDC; Médecins Sans Frontières, France; Coalition for Epidemic Preparedness Innovations; Janssen Vaccines & Prevention B.V.; Public Health England Not yet recruiting
[allAfrica] In late 2018, Sierra Leone's First Lady, Fatima Bio, opened a national campaign "Hands Off Our Girls." Her campaign made big promises to reduce child marriages and teenage pregnancies in the country, in part to tackle the spike in teenage pregnancies following widespread rape during the Ebola crisis. Reflecting on this campaign, President Julius Maada Bio stated: "We have wasted a lot of time in restricting the potentials of women and girls."